Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 8.50 GBp
Change Today -0.62 / -6.85%
Volume 37.7M
AVO On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 12:08 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

advanced oncotherapy plc (AVO) Snapshot

Open
8.38 GBp
Previous Close
9.13 GBp
Day High
8.63 GBp
Day Low
8.13 GBp
52 Week High
04/17/15 - 16.75 GBp
52 Week Low
06/4/14 - 2.45 GBp
Market Cap
91.4M
Average Volume 10 Days
10.5M
EPS TTM
-0.0069 GBp
Shares Outstanding
1.1B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVANCED ONCOTHERAPY PLC (AVO)

Related News

No related news articles were found.

advanced oncotherapy plc (AVO) Related Businessweek News

No Related Businessweek News Found

advanced oncotherapy plc (AVO) Details

Advanced Oncotherapy Plc, together with its subsidiaries, provides medical technology for cancer treatment in the United Kingdom and internationally. The company offers Linac Image Guided Hadron technology, the next generation of radiotherapy with precision guided protons for the treatment of cancer; and Single Dose Intraoperative Radiotherapy technology for the treatment of early stage breast cancer. It is also involved in the development and rental of healthcare related properties. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy Plc in September 2012. Advanced Oncotherapy Plc was incorporated in 2005 and is based in London, the United Kingdom.

13 Employees
Last Reported Date: 06/29/14
Founded in 2005

advanced oncotherapy plc (AVO) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 68.8K GBP
Executive Chairman and Member of Audit Commit...
Total Annual Compensation: 189.0K GBP
Compensation as of Fiscal Year 2013.

advanced oncotherapy plc (AVO) Key Developments

Advanced Oncotherapy Announces Sinophi Healthcare Limited Signs Purchase Agreement for One Light Proton Therapy System to Be Installed in Hospital in China

Advanced Oncotherapy announced that Sinophi Healthcare Limited has signed a purchase agreement for one LIGHT proton therapy system to be installed in a hospital in China. This follows a number of on-going Letters of Intent to purchase the system as well as the announcement of a Harley Street facility to house the first LIGHT machine in London and represents the company's first full commercial purchase order. Sinophi expects to install Advanced Oncotherapy's LIGHT system as part of its oncology hospital project in Huai'an City, in Jiangsu province, East China. The initial purchase price for the accelerator is around USD 40 million with the final price dependent on customisations and treatment options selected by Sinophi. Payment will be satisfied through a schedule of milestone payments. Under the agreement, Advanced Oncotherapy will build and install the LIGHT machine as well as providing long-term maintenance and support once the system has been installed and in addition to this first project, Sinophi has signed an exclusive fifteen year agreement with Advanced Oncotherapy to become the company's first tier distributor for the LIGHT system in China and a number of other countries in Southeast Asia.

Advanced Oncotherapy Plc Signs an Agreement to Lease Harley Street Location

Advanced Oncotherapy Plc announced that it has signed an agreement to lease a Harley Street location, which will become the UK's first Proton Therapy Centre using the company's LIGHT System. The centre will become a hub where patients from London, the rest of the UK and others further afield can have their cancers effectively treated with a proton therapy system. Advanced Oncotherapy has signed an agreement with Howard de Walden Estates Limited granting a 50 year lease for the whole of 141 Harley Street and part of 143 Harley Street to the Company. The properties, which comprise approximately 8,000 sq ft, will be converted for use as a Proton Therapy Centre, and will house the first LIGHT machine to be constructed and operated in the UK. The grant of the lease is subject to the relevant planning and other statutory consents being obtained for the redevelopment of the buildings. The total cost of the redevelopment will be borne by Howard de Walden Estates and is estimated at between £6-7 million. Work will start in July 2015, with the property expected to be handed over to Advanced Oncotherapy by the end of 2016 when the first LIGHT System will be ready, enabling patients to start treatments in 2017. The company also has an agreement with SUNY Upstate Medical University Hospital in Syracuse, Central New York State to build a US based proton therapy facility using the LIGHT system. The facility in Harley Street will be constructed in parallel with the US installation, and the Company is in early discussions with private healthcare providers in the UK to operate in this location.

Advanced Oncotherapy Announces the Manufacture of the First CCL (Coupled Cavity Linac) Module

Advanced Oncotherapy announced that the manufacture of the first CCL (Coupled Cavity Linac) module has been successfully completed. This required a complex design procedure and sophisticated manufacturing process achievable only through a successful collaboration between high-level physicists, scientists, engineers and industrial experience and expertise. The CCL accelerating structures are an essential part of the LIGHT proton therapy system. They consist of a series of cells which accelerate the protons from energies of 37.5 Mega-electron Volts (MeV) to the full 230MeV required to treat all radiosensitive tumours found in a typical clinical setting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVO:LN 8.50 GBp -0.62

AVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVO.
View Industry Companies
 

Industry Analysis

AVO

Industry Average

Valuation AVO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 801.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED ONCOTHERAPY PLC, please visit www.advancedoncotherapy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.